Linked Life Data

16012727

Source:http://linkedlifedata.com/resource/pubmed/id/16012727

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
2005-7-13
pubmed:abstractText
l-leucovorin (LV)/5-fluorouracil (5FU) may play an important role, as an adjuvant chemotherapy, in improving the survival of patients with stage III colorectal cancer. However, severe toxicity of the chemotherapeutic agent could be fatal. Adverse effects, including bone marrow suppression, liver damage, renal damage, and glucose tolerance, were evaluated daily during 3 courses of l-LV/5FU-modified RPMI regimen adjuvant chemotherapy for 22 patients with stage III colorectal cancer. Decrease in the serum levels of neutrophils and platelets occurred in the 1st course, which became more obvious after three or four administrations of l-LV/5FU in the 1st course. Furthermore, serum levels of leukocytes, neutrophils, and platelets on the re-start day of this chemotherapy after 2-week intervals were lower than those on the start day of this chemotherapy. In the evaluation of liver damage, renal damage, and glucose tolerance; serum alanine aminotransferase level in the 2nd course, serum total bilirubin (T.Bil) level in the 1st course, and serum creatinine level in the 1st course deteriorated during the course. T.Bil levels on the re-start day of this chemotherapy after 2-week intervals were especially high compared to that on the start day. The more courses of this chemotherapy we perform, the more attention we must pay to bone marrow suppression and hyperbilirubinemia. Thus, we clarified the attentive point of side effect of l-LV/5FU adjuvant chemotherapy for colorectal cancer.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Aug
pubmed:issn
1021-335X
pubmed:author
pubmed:issnType
Print
pubmed:volume
14
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
433-9
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed-meshheading:16012727-Adult, pubmed-meshheading:16012727-Aged, pubmed-meshheading:16012727-Aged, 80 and over, pubmed-meshheading:16012727-Alanine Transaminase, pubmed-meshheading:16012727-Alkaline Phosphatase, pubmed-meshheading:16012727-Antineoplastic Combined Chemotherapy Protocols, pubmed-meshheading:16012727-Aspartate Aminotransferases, pubmed-meshheading:16012727-Bilirubin, pubmed-meshheading:16012727-Blood Glucose, pubmed-meshheading:16012727-Bone Marrow, pubmed-meshheading:16012727-Chemotherapy, Adjuvant, pubmed-meshheading:16012727-Colorectal Neoplasms, pubmed-meshheading:16012727-Creatinine, pubmed-meshheading:16012727-Drug Administration Schedule, pubmed-meshheading:16012727-Female, pubmed-meshheading:16012727-Fluorouracil, pubmed-meshheading:16012727-Humans, pubmed-meshheading:16012727-Leucovorin, pubmed-meshheading:16012727-Leukocyte Count, pubmed-meshheading:16012727-Male, pubmed-meshheading:16012727-Middle Aged, pubmed-meshheading:16012727-Neoplasm Staging, pubmed-meshheading:16012727-Platelet Count, pubmed-meshheading:16012727-Time Factors, pubmed-meshheading:16012727-Treatment Outcome
pubmed:year
2005
pubmed:articleTitle
Toxicity during l-LV/5FU adjuvant chemotherapy as a modified RPMI regimen for patients with colorectal cancer.
pubmed:affiliation
Department of Surgery, Wakayama Medical University, School of Medicine, Wakayama, Japan.
pubmed:publicationType
Journal Article, Clinical Trial, Comparative Study